Amarantus and Brewer Sports Add Partnership With Cavendish Global to #C4CT Alzheimer's Concussion Awareness Summit at United Nations
Download PDF
MINNEAPOLIS, SAN FRANCISCO and GENEVA, June 11, 2014 (GLOBE NEWSWIRE) -- Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS) and Brewer Sports International (BSI), today announced the addition of Cavendish Global as partner at the 3rd #C4CT (Coalition for Concussion Treatment) Concussion Awareness Summit, on Thursday, July 31, 2014 at the United Nations in New York City, NY. The summit will be focused on the emerging hypothesis that brain injury may increase the risk of Alzheimer's disease.
Cavendish Global provides family offices and their foundations with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the innovative resources required to help develop and implement their individual pro-social impact investment, grant making and philanthropy programs within health and the life sciences.
Mr. Michael Moffat, Cavendish co-founder and President explains, "Brain disorders affect more than 60 million Americans, that's more than one in four Americans suffering from mental illness or brain injury. From autism and Alzheimer's disease to traumatic brain injury (TBI) and post-traumatic stress (PTS), brain ailments cost the U.S. close to $1 trillion each year. Leading scientists have uncovered compelling evidence of the link between Traumatic Brain Injuries and Alzheimer's and Parkinson's disease." Moffat emphasizes, "Cancer and heart disease affect fewer people, yet receive three times more funding support than brain diseases. With recent advances in understanding the link between TBI and brain ailments, there has never been a better time for pro-social family offices and foundations to make a real difference by accelerating the development of new diagnostics and treatments through increased grant-giving and philanthropy in this important area. Cavendish is committed to help make this happen."
To register or for additional information, please visit www.c4ctsummit.com. For further questions, please contact Lindsay Lommel at lindsay.lommel@thebrewergroup.com.
For sponsorship information please visit: http://www.c4ctsummit.com/sponsorship-opportunities.
About Cavendish Global
Cavendish Global consists of over 150 leading family offices and foundations from around the world with combined assets of over $190 billion who share a passion for pro-social endeavors within health and the life sciences. Cavendish provides family offices with a number of innovative resources, which includes Cavendish Impact Forums. A unique gathering of leading family offices, Cavendish Impact Forums take place three times each year; in the United States in May, Europe (London, November 2014) and a third event held at a Cavendish Host Partner City which moves to a different global location each year (Dubai, UAE January 2015). The Cavendish Global Health Impact Forum provides family offices with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the information and educational resources required by foundations actively seeking to accelerate technological innovation and health access through sustainable philanthropy, grant-making, and impact investing. The Forum is also an opportunity for family offices to champion and share information on projects and organizations, which they are passionate about with other family offices from around the world. Cavendish Global Forums are organized together with the Global Partnerships Forum and the New York Academy of Sciences.
For more information: http://cavendishglobal.com.
About Amarantus BioScience Holdings, Inc.
Amarantus BioScience Holdings (AMBS) is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis. AMBS has licensed Eltoprazine ("Eltoprazine"
, a phase 2b ready indication for Parkinson's Levodopa induced dyskinesia and Adult ADHD. AMBS has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test(R)" for Alzheimer's disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF" and is developing MANF-based products as treatments for brain disorders. AMBS also owns intellectual property for the diagnosis of Parkinson's disease ("NuroPro" and the discovery of neurotrophic factors ("PhenoGuard" . Amarantus operations are located at Janssen Labs @QB3 in San Francisco, CA. For further information please visit www.Amarantus.com, or connect with the Company on Facebook, LinkedIn, Twitter and Google+.
Download PDF
MINNEAPOLIS, SAN FRANCISCO and GENEVA, June 11, 2014 (GLOBE NEWSWIRE) -- Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS) and Brewer Sports International (BSI), today announced the addition of Cavendish Global as partner at the 3rd #C4CT (Coalition for Concussion Treatment) Concussion Awareness Summit, on Thursday, July 31, 2014 at the United Nations in New York City, NY. The summit will be focused on the emerging hypothesis that brain injury may increase the risk of Alzheimer's disease.
Cavendish Global provides family offices and their foundations with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the innovative resources required to help develop and implement their individual pro-social impact investment, grant making and philanthropy programs within health and the life sciences.
Mr. Michael Moffat, Cavendish co-founder and President explains, "Brain disorders affect more than 60 million Americans, that's more than one in four Americans suffering from mental illness or brain injury. From autism and Alzheimer's disease to traumatic brain injury (TBI) and post-traumatic stress (PTS), brain ailments cost the U.S. close to $1 trillion each year. Leading scientists have uncovered compelling evidence of the link between Traumatic Brain Injuries and Alzheimer's and Parkinson's disease." Moffat emphasizes, "Cancer and heart disease affect fewer people, yet receive three times more funding support than brain diseases. With recent advances in understanding the link between TBI and brain ailments, there has never been a better time for pro-social family offices and foundations to make a real difference by accelerating the development of new diagnostics and treatments through increased grant-giving and philanthropy in this important area. Cavendish is committed to help make this happen."
To register or for additional information, please visit www.c4ctsummit.com. For further questions, please contact Lindsay Lommel at lindsay.lommel@thebrewergroup.com.
For sponsorship information please visit: http://www.c4ctsummit.com/sponsorship-opportunities.
About Cavendish Global
Cavendish Global consists of over 150 leading family offices and foundations from around the world with combined assets of over $190 billion who share a passion for pro-social endeavors within health and the life sciences. Cavendish provides family offices with a number of innovative resources, which includes Cavendish Impact Forums. A unique gathering of leading family offices, Cavendish Impact Forums take place three times each year; in the United States in May, Europe (London, November 2014) and a third event held at a Cavendish Host Partner City which moves to a different global location each year (Dubai, UAE January 2015). The Cavendish Global Health Impact Forum provides family offices with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the information and educational resources required by foundations actively seeking to accelerate technological innovation and health access through sustainable philanthropy, grant-making, and impact investing. The Forum is also an opportunity for family offices to champion and share information on projects and organizations, which they are passionate about with other family offices from around the world. Cavendish Global Forums are organized together with the Global Partnerships Forum and the New York Academy of Sciences.
For more information: http://cavendishglobal.com.
About Amarantus BioScience Holdings, Inc.
Amarantus BioScience Holdings (AMBS) is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis. AMBS has licensed Eltoprazine ("Eltoprazine"
, a phase 2b ready indication for Parkinson's Levodopa induced dyskinesia and Adult ADHD. AMBS has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test(R)" for Alzheimer's disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF" and is developing MANF-based products as treatments for brain disorders. AMBS also owns intellectual property for the diagnosis of Parkinson's disease ("NuroPro" and the discovery of neurotrophic factors ("PhenoGuard" . Amarantus operations are located at Janssen Labs @QB3 in San Francisco, CA. For further information please visit www.Amarantus.com, or connect with the Company on Facebook, LinkedIn, Twitter and Google+. 
